In 21 MS patients (17 RR-, 4 PP-), peripheral blood sampled two weeks after the first loading dose (300 mg) of OCR showed a complete depletion of CD20-expressing cells (from 224.9 ± 24.6/μL to 0.57 ± 0.18/μL, p < 0.0001), significant also in the sub-group analysis of CD19+ and CD3+CD20+ [17]. The gene discussed is MS4A1; the disease is myeloid sarcoma.